InMed Pharmaceuticals Files Provisional Patent Application for Treating Eye Disease - Video News Alert on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - May 13, 2015) - InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF), has filed a provisional patent application with the United States Patent and Trademark Office relating to the treatment of eye diseases. A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may later want to file for a patent with similar claims.

InvestmentPitch.com has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "InMed" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_xaqfwyqi/InMed-Pharma-CSE-IN-files-provisional-patent-for-treating-eye-diseases

Dr. Sazzad Hossain, CSO of InMed stated: "We are pleased that our R & D efforts have culminated in the filing of a patent application within this large area of unmet medical needs. We have continued to build our expertise in the ocular disease area and believe the application that we have filed with the USPTO allows the Company to pursue a strategic IP strategy around the ocular therapy space including Glaucoma and other ocular diseases."

The company's CTI-085 therapy is being developed to prevent permanent vision damage caused by glaucoma. This novel cannabinoid based dual action ocular therapy not only reduces the elevated intra-ocular pressure in the affected eyes, but also provides necessary neuroprotection for the retinal ganglion cells and other optic nerve tissues.

It is estimated that 2.7 million people in the United States suffer from glaucoma, a number that is expected to reach 4.3 million by 2030.

The company' proprietary bioinformatics tool, known as IDP, is employed to identify individual chemical compounds from cannabis & non-cannabis plants, which can be targeted to develop therapies for specific diseases and conditions, with the additional benefit of reduced side effects.

Craig Schneider, President & CEO, added: "The filing of this patent application supplements our existing intellectual property portfolio and we plan to continue to file additional patent applications covering our technologies and novel therapies that will drive our long-term shareholder value."

InMed's proprietary platform technology, product pipeline, and accelerated development pathway are the fundamental value drivers of the Company.

The shares are trading at $0.25, and with 52.9 million shares outstanding, the company is capitalized at approximately $13.2 million.

For more information, please visit the company's website www.inmedpharma.com or contact Craig Schneider, President & CEO at 604-669-7207 or email info@inmedpharma.com.

Investor relations is handled by Joshua Drumm of Tiberend Strategic Advisors, who can be reached at 212-375-2664 or email jdrumm@tiberend.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com